9P GAIN PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX +/‐ ATEZOLIZUMAB. ARGO: A RANDOMISED PHASE II STUDY

Le résumé fourni par la source

MF/SS has a high degree of inter-tumoral heterogeneity and that molecular signature for each patient tends to remain relatively stable along the disease.Samples corresponding to pre-MF lesions tend to cluster with early MF/SS samples, suggesting that pre-MF lesions indeed correspond to early phases of the disease.On the other hand, patients who progress to advanced stages have a tendency to cluster with each other.Several differentially expressed genes were comparing early and advanced stages.FGFR3, NUAK1, FJX1, CXCL12 and RORC were up regulated in early lesions, while CARD11, CD2, CD38, CD3D, CD3E, CD3G, CXCR4, GZMA, IL10 and SELL were up -regulated in tumors (p < 0,005).Conclusions: Gene-expression profiling using a customized Nano-String platform can be applied to routine paraffin embedded MF/SS samples and provides data that allow to a better understanding of MF genesis and progression.MF/SS samples show an unexpected high degree of inter-tumoral heterogeneity, suggesting that every patient has some individual molecular signature features that are found in consecutive biopsies.The analysis brings also particular gene signatures associated with early MF and progression, allowing recognizing stage-specific signatures.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.